Page 136 - 202007

mune checkpoint blockade in cancer therapy[J]. J Clin On- controlled，phase 3 trial[J]. Lancet，2019，393（10183）：
col，2015，33（17）：1974-U1161. 1819-1830.
[ 3 ] TOPALIAN SL，DRAKE CGPARDOLL DM. Immune [15] SABATOS-PEYTON CA，NEVIN J，BROCK A，et al.
checkpoint blockade：a common denominator approach to Blockade of Tim-3 binding to phosphatidylserine and
cancer therapy[J]. Cancer Cell，2015，27（4）：450-461. CEACAM1 is a shared feature of anti-Tim-3 antibodies
[ 4 ] LI X，SHAO C，SHI Y，et al. Lessons learned from the that have functional efficacy[J]. Oncoimmunology，2018.
blockade of immune checkpoints in cancer immunothera- DOI：10.1080/2162402X.2017.1385690.
py[J]. J Hematol Oncol，2018，11（1）：31-56. [16] XU L，HUANG Y，TAN L，et al. Increased Tim-3 expres-
[ 5 ] WALKER LSK，SANSOM DM. Confusing signals：recent sion in peripheral NK cells predicts a poorer prognosis
progress in CTLA-4 biology[J]. Trends Immunol，2015，36 and Tim-3 blockade improves NK cell-mediated cytotoxic-
（2）：63-70. ity in human lung adenocarcinoma[J]. Int Immunopharma-
[ 6 ] CHAN DV，GIBSON HM，AUFIERO BM，et al. Differen- col，2015，29（2）：635-641.
tial CTLA-4 expression in human CD4 versus CD8 T [17] ANDERSON AC，JOLLER N，KUCHROO VK. Lag-3，
+
+
cells is associated with increased NFAT1 and inhibition of Tim-3，and TIGIT：co-inhibitory receptors with special-
+
CD4 proliferation[J]. Genes Immun，2014，15（1）：25-32. ized functions in immune regulation[J]. Immunity，2016，
[ 7 ] HARGADON KM，JOHNSON CE，WILLIAMS CJ. Im- 44（5）：989-1004.
mune checkpoint blockade therapy for cancer：an over- [18] Samsung Medical Center，Symphogen AS，Changhai Hos-
view of FDA-approved immune checkpoint inhibitors[J]. pital，et al. TIM-3 inhibitor clinical studies[EB/OL].
Int Immunopharmacol，2018，62（1）：29-39. [2019-12-23].https：//clinicaltrials.gov/ct2/results?cond=
[ 8 ] HODI FS，O’DAY SJ，MCDERMOTT DF，et al. Improved TIM-3&term=&cntry=&state=&city=&dist=.
survival with ipilimumab in patients with metastatic mela- [19] WAIGHT J，IYER P，BREOUS-NYSTROM E，et al. IN-
noma[J]. New Engl J Med，2010，363（8）：711-723. CAGN02390，a novel antagonist antibody that targets the
[ 9 ] ITO A，KONDO S，TADA K，et al. Clinical development co-inhibitory receptor TIM-3[J]. Cancer Research，2018.
of immune checkpoint inhibitors[J]. Bio Med Res Int， DOI：10.1158/1538-7445.AM2018-3825.
2015.DOI：10.1155/2015/605478. [20] YU X，HUANG X，CHEN X，et al. Characterization of a
[10] RIBAS A，KEFFORD R，MARSHALL MA，et al. Phase novel anti-human lymphocyte activation gene 3（LAG-3）
Ⅲ randomized clinical trial comparing tremelimumab antibody for cancer immunotherapy[J]. MAbs，2019，11
with standard-of-care chemotherapy in patients with ad- （6）：1139-1148.
vanced melanoma[J]. J Clin Oncol，2013，31（5）：616- [21] TAKAYA S，SAITO H，IKEGUCHI M. Upregulation of
622. immune checkpoint molecules，PD-1 and LAG-3，on
[11] MAIO M，SCHERPEREEL A，CALABRO L，et al. Tre- CD4 and CD8 T cells after gastric cancer surgery[J]. Yo-
+
+
melimumab as second-line or third-line treatment in re- nago Acta Med，2015，58（1）：39-58.
lapsed malignant mesothelioma（DETERMINE）：a multi- [22] WANG J，SANMAMED MF，DATAR I，et al. Fibrino-
centre，international，randomised，double-blind，place- gen-like protein 1 is a major immune inhibitory ligand of
bo-controlled phase 2b trial[J]. Lancet Oncol，2017，18 LAG-3[J]. Cell，2019，176（1/2）：334-347.
（9）：1261-1273. [23] SEGA EI，LEVESON-GOWER DB，FLOREK M，et al.
[12] SAHNI S，VALECHA G，SAHNI A. Role of anti-PD-1 an- Role of lymphocyte activation gene-3（Lag-3）in conven-
tibodies in advanced melanoma：the era of immunotherapy tional and regulatory T cell function in allogeneic trans-
[J]. Cureus，2018.DOI：10.7759/cureus.3700. plantation[J]. PLoS One，2014. DOI：10.1371/journal.
[13] ARASANZ H，GATO-CANAS M，ZUAZO M，et al. PD1 pone.0086551.
signal transduction pathways in T cells[J]. Oncotarget， [24] MARUHASHI T，OKAZAKI IM，SUGIURA D，et al.
2017，8（31）：51936-51945. LAG-3 inhibits the activation of CD4 T cells that recog-
+
[14] MOKTS K，WU YL，KUDABA I，et al. Pembrolizumab nize stable pMHCⅡ through its conformation-dependent
versus chemotherapy for previously untreated，PD-L1-ex- recognition of pMHCⅡ[J]. Nat Immunol，2018，19（12）：
pressing，locally advanced or metastatic non-small-cell 1415-1426.
lung cancer（KEYNOTE-042）：a randomised，open-label， [25] Bristol-myers Squibb，Nation Cancer Institute，Vanderbilt-

·894 · China Pharmacy 2020 Vol. 31 No. 7 中国药房 2020年第31卷第7期